Encara no tenim significats per a "responding patients".
1Induction of tertiary lymphoid structures upon treatment was observed in responding patients.
2Conclusion: We conclude that maintenance chemotherapy in responding patients is beneficial in SCLC.
3Treatment of older and non responding patients is not yet standardized.
4Among the responding patients, the median time to treatment failure was 8 months.
5These specific combinations were virtually absent in the combinations with few responding patients.
6The central nervous system was the initial site of relapse in 11 responding patients.
7Maintenance therapy for stable or responding patients was combined therapy.
8Patients received three courses of chemotherapy before resection, and responding patients received two courses postoperatively.
9Chemotherapy could be stopped after ≥6 cycles in responding patients, trastuzumab was continued until progression.
10Patient immune parameters have recently been associated with response to chemotherapy and may identify responding patients.
11Response was assessed after three courses and chemotherapy was continued in responding patients until best response.
12All responding patients have been maintained on therapy.
13Among responding patients, the initial favorable response to chemotherapy was apparent after the first course of chemotherapy.
14The median survival was 21 weeks overall and 45 weeks for responding patients.
15EPC levels fell in responding patients.
16The biopharmaceutical company said a combination of its drug Telcyta with carboplatin and paclitaxel improved survival in responding patients.
Aquesta col·locació està formada per:
Responding patients a través del temps
Responding patients per variant geogràfica